Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $553.62 | 4 | 87.4% |
| Education | $79.95 | 1 | 12.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $379.57 | 3 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $129.00 | 1 | $0 (2020) |
| Amgen Inc. | $125.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $129.00 | 1 | AstraZeneca Pharmaceuticals LP ($129.00) |
| 2019 | $125.00 | 1 | Amgen Inc. ($125.00) |
| 2018 | $124.62 | 1 | Shire North American Group Inc ($124.62) |
| 2017 | $254.95 | 2 | Shire North American Group Inc ($254.95) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/14/2020 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $129.00 | General |
| Category: Respiratory | ||||||
| 06/04/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 10/26/2018 | Shire North American Group Inc | VPRIV (Biological) | Food and Beverage | In-kind items and services | $124.62 | General |
| Category: GENETIC DISEASE | ||||||
| 05/09/2017 | Shire North American Group Inc | ELAPRASE (Biological) | Education | In-kind items and services | $79.95 | General |
| Category: GENETIC DISEASE | ||||||
| 04/21/2017 | Shire North American Group Inc | VPRIV (Biological) | Food and Beverage | In-kind items and services | $175.00 | General |
| Category: GENETIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 534 | 606 | $141,510 | $35,157 |
| 2022 | 8 | 701 | 790 | $175,535 | $54,020 |
| 2021 | 5 | 688 | 744 | $184,415 | $57,799 |
| 2020 | 8 | 636 | 705 | $175,280 | $48,690 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 251 | 294 | $84,900 | $22,446 | 26.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 70 | 70 | $28,140 | $6,406 | 22.8% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2023 | 76 | 79 | $12,625 | $2,395 | 19.0% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 39 | 48 | $7,920 | $1,946 | 24.6% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 33 | 35 | $5,250 | $1,212 | 23.1% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 13 | 26 | $1,600 | $421.72 | 26.4% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 15 | 15 | $750.00 | $243.00 | 32.4% |
| 81003 | Automated urinalysis test | Office | 2023 | 37 | 39 | $325.00 | $85.80 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 307 | 362 | $94,285 | $33,308 | 35.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 101 | 101 | $39,000 | $11,180 | 28.7% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 161 | 175 | $26,250 | $6,099 | 23.2% |
| 87428 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | Office | 2022 | 54 | 56 | $10,640 | $1,705 | 16.0% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 17 | 18 | $2,900 | $910.22 | 31.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 16 | 32 | $1,600 | $519.36 | 32.5% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 14 | 14 | $700.00 | $228.08 | 32.6% |
| 81003 | Automated urinalysis test | Office | 2022 | 31 | 32 | $160.00 | $71.02 | 44.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 253 | 291 | $75,880 | $27,807 | 36.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 168 | 168 | $64,680 | $19,929 | 30.8% |
| 87426 | Elisa detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 209 | 224 | $33,600 | $7,914 | 23.6% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 38 | 41 | $10,150 | $2,104 | 20.7% |
| 81003 | Automated urinalysis test | Office | 2021 | 20 | 20 | $105.00 | $45.00 | 42.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 260 | 298 | $77,720 | $22,072 | 28.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 172 | 172 | $66,265 | $19,164 | 28.9% |
| 87426 | Coronavirus ag ia | Office | 2020 | 117 | 126 | $18,900 | $4,452 | 23.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 16 | $6,080 | $1,250 | 20.6% |
About Dr. Sergey Galustyan, M.D
Dr. Sergey Galustyan, M.D is a Pediatric Emergency Medicine healthcare provider based in Jamaica, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053418095.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sergey Galustyan, M.D has received a total of $633.57 in payments from pharmaceutical and medical device companies, with $129.00 received in 2020. These payments were reported across 5 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($553.62).
As a Medicare-enrolled provider, Galustyan has provided services to 2,559 Medicare beneficiaries, totaling 2,845 services with total Medicare billing of $195,666. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Pediatric Emergency Medicine
- Location Jamaica, NY
- Active Since 09/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207PP0204X
- Entity Type Individual
- NPI Number 1053418095
Products in Payments
- VPRIV (Biological) $299.62
- FASENRA (Drug) $129.00
- Aimovig (Biological) $125.00
- ELAPRASE (Biological) $79.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Emergency Medicine Doctors in Jamaica
Dr. Razia Siddique, Md, MD
Pediatric Emergency Medicine — Payments: $260.54
Dr. Mercedes Lebajo, Md, MD
Pediatric Emergency Medicine — Payments: $32.40
Dr. Dakshayani Guttal, M.d, M.D
Pediatric Emergency Medicine — Payments: $26.94
Dr. Vipin Agarwalla, M.d, M.D
Pediatric Emergency Medicine — Payments: $21.17
Mr. Steven Sherman, Md, MD
Pediatric Emergency Medicine — Payments: $11.72
Dr. Veena Bhagat, Md, MD
Pediatric Emergency Medicine